Clinical assessment of topiramate therapy in patients with migrainous vertigo.
OBJECTIVE
To assess the efficacy of topiramate in reducing both the frequency and the severity of vertigo and headache attacks in patients with migrainous vertigo and to compare 50 and 100 mg/day doses of the drug.


METHODS
Thirty patients diagnosed as definite migrainous vertigo were recruited in the study. Vertigo and headache frequency was determined as the monthly number of attacks whereas severity was determined by visual analog scales measured in millimeters from 0 to 100. Patients were randomized to either 50 or 100 mg/day topiramate for 6 months. Vertigo and headache frequency and severity were evaluated at the end of the study period.


RESULTS
Number of mothly vertigo attacks decreased significantly in the overall group after treatment (median from 5.5 to 1; P < .01). The same was true for monthly headache attacks (median from 4 to 1; P < .01). A statically significant improvement in vertigo severity was noted (median from 80 to 20 mm; P < .01). Headache severity showed significant improvement as well (median from 60 to 30 mm; P < .01). No statistically significant difference between high- and low-dose groups was present regarding efficacy (P > .05). Four patients in the high-dose group discontinued treatment at the end of the first month because of adverse effects.


CONCLUSIONS
In the overall group, topiramate was found to be effective in reducing the frequency and the severity of vertigo and headache attacks. Both doses of the drug were equally efficacious. The 50 mg/day dose seems to be appropriate as higher adverse effects were noted when 100 mg/day was used.
Gode
Sercan
S
Ege University Medical School Department of Otolaryngology Bornova, Izmir, Turkey.
Celebisoy
Nese
N
Kirazli
Tayfun
T
Akyuz
Aycan
A
Bilgen
Cem
C
Karapolat
Hale
H
Sirin
Hadiye
H
Gokcay
Figen
F
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D003952:Diagnostic Imaging; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D009460:Neurologic Examination; D017063:Outcome Assessment, Health Care; D000077236:Topiramate; D016896:Treatment Outcome; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D055815:Young Adult
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose